NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland, Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are available after first line chemotherapy. The combination of ipilimumab and nivolumab has recently shown increased survival compared to standard chemotherapy, but most patients do not respond and improvements are called for. Telomerase is expressed in mesothelioma cells, but only sparsely in normal tissues and is therefore an attractive target for therapeutic vaccination. Vaccination against telomerase is tolerable and has shown to induce immune responses associated with increased survival in other cancer types. There is a well-founded scientific rationale for the combination of a telomerase vaccine and checkpoint inhibition to improve treatment response in MPM patients.

Methods: NIPU is a randomized, multi-centre, open-label, phase II study comparing the efficacy and safety of nivolumab and ipilimumab with or without telomerase vaccine in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy. Participants (n = 118) are randomized 1:1 into two treatment arms. All participants receive treatment with nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) until disease progression, unacceptable toxicity or for a maximum of 2 years. Patients randomised to the experimental arm receive 8 intradermal injections of UV1 vaccine during the first three months of treatment. Tumour tissue, blood, urine, faeces and imaging will be collected for biomarker analyses and exploration of mechanisms for response and resistance to therapy.

Discussion: Checkpoint inhibition is used for treatment of mesothelioma, but many patients still do not respond. Increasing therapy response to immunotherapy is an important goal. Possible approaches include combination with chemotherapy, radiotherapy, targeted therapy and other immunotherapeutic agents. Predictive biomarkers are necessary to ensure optimal treatment for each patient and to prevent unnecessary side effects. This trial seeks to improve treatment response by combining checkpoint inhibition with a telomerase vaccine and also to explore mechanisms for treatment response and resistance. Knowledge gained in the NIPU study may be transferred to the first line setting and to other cancers with limited benefit from immunotherapy.

Trial registration: ClinicalTrials.gov: NCT04300244, registered March 8th, 2020, https://ichgcp.net/clinical-trials-registry/NCT04300244?term=NIPU&draw=2&rank=1 .

Keywords: Biomarker; Immune response; Immunotherapy; Ipilimumab; Malignant pleural mesothelioma; Nivolumab; Telomerase vaccine; hTERT.

Conflict of interest statement

EBE is employed by Ultimovacs ASA. AKN has participated as a consultant for Bristol Meyers Squibb. The remaining authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study design of the NIPU trial. Patients with MPM and progression after first line platinum-based chemotherapy are randomised (1:1) to ipilimumab and nivolumab alone or in combination with UV1 vaccine.

References

    1. Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg. 2018;105:432–437. doi: 10.1016/j.athoracsur.2017.09.036.
    1. Katzman D, Sterman DH. Updates in the diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Pulm Med. 2018;24:319–326. doi: 10.1097/MCP.0000000000000489.
    1. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Skakibara J, Ishimine A, et al. CD8 + tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother. 2010;59:1543–1549. doi: 10.1007/s00262-010-0881-6.
    1. Cedrés S, Ponce-aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Medivil A, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) PLoS ONE. 2015;1:1–12. doi: 10.1371/journal.pone.0121071.
    1. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma ( KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet. 2017;18:623–630. doi: 10.1016/S1470-2045(17)30169-9.
    1. Quispel-janssen J, Van Der NV, De VJF, Zimmerman M, Lalezari F, Thunnissen E, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569–1576. doi: 10.1016/j.jtho.2018.05.038.
    1. Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, et al. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2020;5:351–357. doi: 10.1001/jamaoncol.2018.5428.
    1. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. Articles first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;6736:1–12. doi: 10.1016/S0140-6736(20)32714-8.
    1. Ranki T, Joensuu T, Elke J, Karbach J, Wahle C, Kairemo K, et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 C T-cell response, prominent in filtration of CD8 C lymphocytes and Th1 type polarization. Oncoimmunology. 2014;3:e958937. doi: 10.4161/21624011.2014.958937.
    1. Zanetti M. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol. 2017;14:115–128. doi: 10.1038/nrclinonc.2016.67.
    1. Armato SG, Nowak AK. Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1) J Thorac Oncol. 2018;13:1012–1021. doi: 10.1016/j.jtho.2018.04.034.
    1. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–260. doi: 10.1093/annonc/mdh059.
    1. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, et al. Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013;32:4203–4213. doi: 10.1038/onc.2012.441.
    1. Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 2018;592:2023–2031. doi: 10.1002/1873-3468.13084.
    1. Stewart SA, Hahn WC, Connor BFO, Banner EN, Lundberg AS, Modha P, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. PNAS. 2002;99:1–6. doi: 10.1073/pnas.182407599.
    1. Dhaene K, Hübner R, Kumar-singh S, Weyn B, Van ME. Telomerase activity in human pleural mesothelioma. Thorax. 1998;53:915–918. doi: 10.1136/thx.53.11.915.
    1. Tallet A, Nault J, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene. 2014;33:3748–3752. doi: 10.1038/onc.2013.351.
    1. Taga S, Osaki T, Ohgami A, Imoto H, Yasumoto K. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg. 1999;230:715–720. doi: 10.1097/00000658-199911000-00015.
    1. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer. 2013;108:278–284. doi: 10.1038/bjc.2012.602.
    1. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874–1881. doi: 10.1093/jnci/89.24.1874.
    1. Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, et al. Distinct prognostic value of circulating anti-telomerase CD4 + Th1 immunity and exhausted PD-1 +/TIM-3 + T cells in lung cancer. Br J Cancer. 2019;121:405–416. doi: 10.1038/s41416-019-0531-5.
    1. Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, et al. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunol Immunother. 2017;66:891–901. doi: 10.1007/s00262-017-1994-y.
    1. Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-reisse CH, Rasch W, Kyte JA, et al. Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer. Front Immunol. 2020;11:1–12. doi: 10.3389/fimmu.2020.572172.
    1. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J Immunother. 2015;38:1–11. doi: 10.1097/CJI.0000000000000062.PD-1/PD-L1.
    1. Curran MA, Glisson BS. New hope for therapeutic cancer vaccines in the era of immune checkpoint modulation. Ann Rev Med. 2019;70:109–124. doi: 10.1146/annurev-med-050217-121900.
    1. Wei SC, Sharma R, Anang NAS, Levine JH, Mancuso JJ, Setty M, et al. Negative costimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity. 2019;50:1084–1098. doi: 10.1016/j.immuni.2019.03.004.Negative.
    1. Wei SC, Levine JH, Wargo JA, Pe D, Allison JP, Wei SC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120–1125.e17. doi: 10.1016/j.cell.2017.07.024.
    1. Disselhorst MJ, Quispel-janssen J, Lalezari F, Monkhorst K, De VJF, Van Der NV, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE ): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7:260–270. doi: 10.1016/S2213-2600(18)30420-X.
    1. Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med. 2012;42:267–280. doi: 10.1053/j.semnuclmed.2012.02.003.
    1. Sa R, Zhao HG, Dai YY, Guan F. The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions. Med (United States) 2018;97:e12521. doi: 10.1097/MD.0000000000012521.
    1. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–1444. doi: 10.1093/annonc/mdy103.
    1. Zitvogel L, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359:1366–1370. doi: 10.1126/science.aar6918.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe